Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
Crowded places can be viewed as dangerous for those with osteoporosis, whose bones are more likely to break. Even a small bump can result in a fracture. #OsteoporosisInsights #ACTonFractures https://t.co/miZ8daRMiB https://t.co/iRSV9nhrPf
— UCB News (@ucb_news) 22.07.2018 -
UCB is committed to a positive impact on the global communities where patients live. Since 2013, UCB has partnered with Project Hope, a humanitarian organisation, on an initiative known as ‘Rainbow Bridge’ to help people with epilepsy in China #UCB90 https://t.co/MLiKOuiIkX
— UCB News (@ucb_news) 19.07.2018 -
Today on Biomedical Science Day, UCB is celebrating all the amazing work carried out in laboratories around the world, and those who are using their research to #ACTonFractures. Find out more about our #Osteoporosis research here: https://t.co/n3Y3zc4v6M https://t.co/MkHjMkxoLX
— UCB News (@ucb_news) 19.07.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
